SIRPA and neoplasm: These data suggest that, in addition to a restoration of myeloid cell phagocytic potential along with enhanced antigen processing and presentation capabilities, SIRPα blockade partially restores M-MDSC maturation and reduces the recruitment of suppressive myeloid cell subtypes into the tumor.